The pharmaceutical company said promising pipeline developments and high demand for drugs in its specialty segment lifted ...
GSK Plc (NYSE:GSK) reported fourth-quarter sales of $10.40 billion (8.12 billion Sterling Pounds), up 1% year-over-year and ...
While vaccine sales dropped, GSK raised its revenue guidance for 2031 with speciality medicines expected to drive that growth ...
Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...
GSK reports better-than-expected Q4 earnings. It also announces a new share buyback program and raises the long-term sales outlook for 2031 by $2 billion.
Pharma giant GSK surged to the top of the index as it missed forecasts slightly with its annual results, but raised its ...
Stock prices in London were mixed on Wednesday afternoon, with a share price rise for GSK supporting the FTSE 100, though tariff worries continue to hang over equities. The FTSE 100 index rose 12.01 ...
British pharmaceutical group GSK on Wednesday reported a near halving of net profit in 2024 after settling hefty US lawsuits over its Zantac heartburn drug.
London stocks were still a touch higher by midday on Wednesday as investors continued to mull the impact of Trump’s trade war ...
GSK said pretax profit in 2024 fell 43% to GBP3.48 billion from GBP6.06 billion a year prior, though revenue increased 3.5% to GBP31.38 billion from GBP30.33 billion, ahead of the GBP31.05 billion ...
If the GSK (LSE: GSK) share price was a video game, it would be flashing GAME OVER to me right now. Shares in the pharmaceutical giant started 2025 trading at a 12-month low. Although they picked ...
GSK’s 6% results-day share price advance is the standout performance in an otherwise subdued FTSE 100 index. Miner Fresnillo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback